Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$57.02 USD

57.02
567,398

+0.73 (1.30%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $57.03 +0.01 (0.02%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPSM

Teladoc Health (TDOC) Down 8.1% Since Q4 Earnings Release

by Zacks Equity Research

Teladoc Health's (TDOC) fourth-quarter results bear the brunt of escalating expenses. Management expects 2023 revenues within $2,550-$2,675 million, way higher than the 2022 figure.

IDEXX (IDXX) Global Sales, Instrument Placement Robust

by Zacks Equity Research

IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.

Select Medical (SEM) Q4 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Select Medical (SEM) anticipates 2023 revenues to be within $6.5-$6.7 billion.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails

by Zacks Equity Research

Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.

Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up

by Zacks Equity Research

Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.

Medtronic (MDT) Receives CE Mark Approval For Aurora System

by Zacks Equity Research

Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.

Pediatrix (MD) Q4 Earnings miss on High Operating Expenses

by Zacks Equity Research

Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.

Edwards Lifesciences (EW) Gains on Innovation, Margin Growth

by Zacks Equity Research

In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.

AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates

by Zacks Equity Research

Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.

AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.29% and 5.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.

Here's Why You Should Add Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Quest Diagnostics (DGX) New Pact to Boost Laboratory Services

by Zacks Equity Research

Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.

Thermo Fisher (TMO) Rides on Strong End Markets, New Launches

by Zacks Equity Research

Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

by Zacks Equity Research

Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.

ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers

by Zacks Equity Research

ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.